These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 27866718)

  • 1. Mutational analysis of metastatic lymph nodes from papillary thyroid carcinoma in adult and pediatric patients.
    Shifrin AL; Fischer M; Paul T; Erler B; Gheysens K; Baodhankar P; Song-Yang JW; Taylor S; Timmaraju VA; Topilow A; Mireskandari A; Kumar G
    Surgery; 2017 Jan; 161(1):176-187. PubMed ID: 27866718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clonal analysis of bilateral, recurrent, and metastatic papillary thyroid carcinomas.
    Wang W; Wang H; Teng X; Wang H; Mao C; Teng R; Zhao W; Cao J; Fahey TJ; Teng L
    Hum Pathol; 2010 Sep; 41(9):1299-309. PubMed ID: 20471663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic prediction of BRAF(V600E) and its relationship with sodium iodide symporter in classic variant of papillary thyroid carcinomas.
    Gao WL; Wie LL; Chao YG; Wie L; Song TL
    Clin Lab; 2012; 58(9-10):919-26. PubMed ID: 23163107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature.
    Krishnamurthy A; Ramshankar V; Murherkar K; Vidyarani S; Raghunandhan GC; Das A; Desai PB; Albert K
    Indian J Cancer; 2017; 54(1):372-378. PubMed ID: 29199726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
    Jeon MJ; Chun SM; Lee JY; Choi KW; Kim D; Kim TY; Jang SJ; Kim WB; Shong YK; Song DE; Kim WG
    Endocrine; 2019 Apr; 64(1):130-138. PubMed ID: 30645724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follicular variant of papillary thyroid carcinoma (FVPTC): histological features, BRAF V600E mutation, and lymph node status.
    Walts AE; Mirocha JM; Bose S
    J Cancer Res Clin Oncol; 2015 Oct; 141(10):1749-56. PubMed ID: 25702102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF genetic heterogeneity in papillary thyroid carcinoma and its metastasis.
    Walts AE; Pao A; Sacks W; Bose S
    Hum Pathol; 2014 May; 45(5):935-41. PubMed ID: 24746198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between the BRAF V600E mutation status and the clinicopathologic features of papillary thyroid carcinoma.
    Shi CL; Sun Y; Ding C; Lv YC; Qin HD
    Genet Mol Res; 2015 Jul; 14(3):7377-85. PubMed ID: 26214416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
    Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
    J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.
    Kim J; Giuliano AE; Turner RR; Gaffney RE; Umetani N; Kitago M; Elashoff D; Hoon DS
    Ann Surg; 2006 Nov; 244(5):799-804. PubMed ID: 17060774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Papillary thyroid carcinomas with cervical lymph node metastases can be stratified into clinically relevant prognostic categories using oncogenic BRAF, the number of nodal metastases, and extra-nodal extension.
    Ricarte-Filho J; Ganly I; Rivera M; Katabi N; Fu W; Shaha A; Tuttle RM; Fagin JA; Ghossein R
    Thyroid; 2012 Jun; 22(6):575-84. PubMed ID: 22471242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nuclear morphometric findings in undetermined cytology: A possible clue for prediction of BRAF mutation in papillary thyroid carcinomas.
    Mungan S; Ersoz S; Saygin I; Sagnak Z; Cobanoglu U
    Endocr Res; 2017 May; 42(2):138-144. PubMed ID: 27911099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF and RAS Mutational Status in Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features and Invasive Subtype of Encapsulated Follicular Variant of Papillary Thyroid Carcinoma in Korea.
    Kim M; Jeon MJ; Oh HS; Park S; Kim TY; Shong YK; Kim WB; Kim K; Kim WG; Song DE
    Thyroid; 2018 Apr; 28(4):504-510. PubMed ID: 29439609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of plasma BRAF(V600E) mutation is associated with lung metastasis in papillary thyroid carcinomas.
    Kim BH; Kim IJ; Lee BJ; Lee JC; Kim IS; Kim SJ; Kim WJ; Jeon YK; Kim SS; Kim YK
    Yonsei Med J; 2015 May; 56(3):634-40. PubMed ID: 25837167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
    Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
    PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classic Architecture with Multicentricity and Local Recurrence, and Absence of TERT Promoter Mutations are Correlates of BRAF (V600E) Harboring Pediatric Papillary Thyroid Carcinomas.
    Onder S; Ozturk Sari S; Yegen G; Sormaz IC; Yilmaz I; Poyrazoglu S; Sanlı Y; Giles Senyurek Y; Kapran Y; Mete O
    Endocr Pathol; 2016 Jun; 27(2):153-61. PubMed ID: 26951110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Papillary thyroid carcinoma with extensive squamous dedifferentiation metastatic to the lung: BRAF mutational analysis as a useful tool to rule out tumor to tumor metastasis.
    Acosta AM; Pins MR
    Virchows Arch; 2016 Feb; 468(2):239-42. PubMed ID: 26521063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.